Zacks Research Has Bullish Estimate for TEVA Q2 Earnings

Teva Pharmaceutical Industries Limited (NYSE:TEVA) – Research analysts at Zacks Research increased their Q2 2025 EPS estimates for shares of Teva Pharmaceutical Industries in a research note issued on Thursday, April 3rd. Zacks Research analyst R. Department now anticipates that the company will earn $0.61 per share for the quarter, up from their previous estimate of $0.60. The consensus estimate for Teva Pharmaceutical Industries’ current full-year earnings is $2.50 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries’ Q2 2025 earnings at $0.61 EPS, Q3 2025 earnings at $0.71 EPS, Q3 2025 earnings at $0.71 EPS, Q1 2027 earnings at $0.62 EPS and Q1 2027 earnings at $0.62 EPS.

A number of other equities analysts also recently issued reports on TEVA. Barclays lowered their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, January 30th. Piper Sandler increased their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research report on Friday, January 17th. Bank of America reduced their price target on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, March 6th. UBS Group dropped their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a report on Thursday, January 30th. Finally, StockNews.com upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Friday. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $23.43.

Teva Pharmaceutical Industries Trading Down 6.9 %

NYSE:TEVA opened at $13.83 on Friday. Teva Pharmaceutical Industries has a 1 year low of $12.51 and a 1 year high of $22.80. The stock has a market cap of $15.68 billion, a P/E ratio of -9.54, a P/E/G ratio of 1.44 and a beta of 0.82. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The stock has a 50-day simple moving average of $16.52 and a 200-day simple moving average of $18.01.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Several institutional investors have recently added to or reduced their stakes in TEVA. Versant Capital Management Inc grew its stake in shares of Teva Pharmaceutical Industries by 437.8% in the 1st quarter. Versant Capital Management Inc now owns 5,297 shares of the company’s stock valued at $81,000 after purchasing an additional 4,312 shares during the last quarter. Central Pacific Bank Trust Division grew its position in Teva Pharmaceutical Industries by 25.0% in the 1st quarter. Central Pacific Bank Trust Division now owns 53,030 shares of the company’s stock valued at $815,000 after buying an additional 10,603 shares during the last quarter. Wellington Management Group LLP increased its stake in Teva Pharmaceutical Industries by 2.1% in the 4th quarter. Wellington Management Group LLP now owns 185,912 shares of the company’s stock valued at $4,098,000 after buying an additional 3,816 shares during the period. Centaurus Financial Inc. raised its position in Teva Pharmaceutical Industries by 97.2% during the 4th quarter. Centaurus Financial Inc. now owns 35,279 shares of the company’s stock worth $778,000 after buying an additional 17,388 shares during the last quarter. Finally, Siemens Fonds Invest GmbH purchased a new position in Teva Pharmaceutical Industries during the 4th quarter worth $611,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.